Eli Lilly and Company (NYSE:LLY) Shares Acquired by Sippican Capital Advisors

Sippican Capital Advisors increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 21.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 4,677 shares of the company’s stock after acquiring an additional 841 shares during the quarter. Eli Lilly and Company makes up approximately 2.1% of Sippican Capital Advisors’ portfolio, making the stock its 7th largest position. Sippican Capital Advisors’ holdings in Eli Lilly and Company were worth $2,726,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in LLY. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $27,000. Retirement Group LLC lifted its position in shares of Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares during the period. Cornerstone Planning Group LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $33,000. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $35,000. Finally, Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $36,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock traded up $2.50 during midday trading on Monday, reaching $754.14. 1,259,770 shares of the company’s stock traded hands, compared to its average volume of 3,077,203. The company has a 50-day simple moving average of $761.77 and a two-hundred day simple moving average of $654.08. Eli Lilly and Company has a 1-year low of $367.35 and a 1-year high of $800.78. The company has a market cap of $716.55 billion, a price-to-earnings ratio of 131.64, a PEG ratio of 1.65 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period last year, the firm earned $2.09 EPS. On average, analysts anticipate that Eli Lilly and Company will post 12.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $815.00 price objective on shares of Eli Lilly and Company in a research report on Monday, April 1st. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Bank of America increased their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, The Goldman Sachs Group increased their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders sold 133,785 shares of company stock valued at $86,537,034. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.